Overview

A Phase I Study to Assess LBL-047 in Healthy Adults and Patients With Systemic Lupus Erythematosus

Status:
RECRUITING
Trial end date:
2027-12-16
Target enrollment:
Participant gender:
Summary
A Phase I, Double-Blind, Randomized, Placebo-Controlled, Dose-Escalation Study of Single Subcutaneous Injections of LBL-047 in Healthy Adults and Patients with systemic lupus erythematosus.
Phase:
PHASE1
Details
Lead Sponsor:
Nanjing Leads Biolabs Co.,Ltd
Collaborator:
Shanghai Public Health Clinical Center
Treatments:
Injections